JP2017530691A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017530691A5 JP2017530691A5 JP2017501231A JP2017501231A JP2017530691A5 JP 2017530691 A5 JP2017530691 A5 JP 2017530691A5 JP 2017501231 A JP2017501231 A JP 2017501231A JP 2017501231 A JP2017501231 A JP 2017501231A JP 2017530691 A5 JP2017530691 A5 JP 2017530691A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- seq
- antibody
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 37
- 238000000034 method Methods 0.000 claims 36
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 33
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 33
- 239000005557 antagonist Substances 0.000 claims 32
- 206010028980 Neoplasm Diseases 0.000 claims 29
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 26
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 26
- 239000000523 sample Substances 0.000 claims 19
- 238000011319 anticancer therapy Methods 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 210000001519 tissue Anatomy 0.000 claims 8
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 7
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 6
- 210000002865 immune cell Anatomy 0.000 claims 6
- 210000004881 tumor cell Anatomy 0.000 claims 6
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 claims 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 5
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 108091006020 Fc-tagged proteins Proteins 0.000 claims 4
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 4
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 4
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 239000012472 biological sample Substances 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000004064 dysfunction Effects 0.000 claims 4
- 208000026278 immune system disease Diseases 0.000 claims 4
- 238000010166 immunofluorescence Methods 0.000 claims 4
- 238000003364 immunohistochemistry Methods 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 208000014018 liver neoplasm Diseases 0.000 claims 4
- 229960003301 nivolumab Drugs 0.000 claims 4
- 229960002621 pembrolizumab Drugs 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- 238000002965 ELISA Methods 0.000 claims 3
- 238000001514 detection method Methods 0.000 claims 3
- 229950009791 durvalumab Drugs 0.000 claims 3
- 238000000684 flow cytometry Methods 0.000 claims 3
- 238000003119 immunoblot Methods 0.000 claims 3
- 201000007270 liver cancer Diseases 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000037581 Persistent Infection Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 206010061934 Salivary gland cancer Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 208000009956 adenocarcinoma Diseases 0.000 claims 2
- 229950002916 avelumab Drugs 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000003914 endometrial carcinoma Diseases 0.000 claims 2
- 230000002357 endometrial effect Effects 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 230000036039 immunity Effects 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 201000002628 peritoneum cancer Diseases 0.000 claims 2
- 201000003804 salivary gland carcinoma Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 229950007213 spartalizumab Drugs 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 210000002536 stromal cell Anatomy 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 208000012991 uterine carcinoma Diseases 0.000 claims 2
- 201000005102 vulva cancer Diseases 0.000 claims 2
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 claims 1
- 206010073069 Hepatic cancer Diseases 0.000 claims 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- 206010047741 Vulval cancer Diseases 0.000 claims 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 229960003852 atezolizumab Drugs 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 239000003966 growth inhibitor Substances 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- 102000048776 human CD274 Human genes 0.000 claims 1
- 229940127121 immunoconjugate Drugs 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000002250 liver carcinoma Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005296 lung carcinoma Diseases 0.000 claims 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims 1
- 210000001161 mammalian embryo Anatomy 0.000 claims 1
- 239000012188 paraffin wax Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021212093A JP2022061983A (ja) | 2014-07-11 | 2021-12-27 | 抗ｐｄ－ｌ１抗体及びその診断上の使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462023741P | 2014-07-11 | 2014-07-11 | |
| US62/023,741 | 2014-07-11 | ||
| PCT/US2015/033395 WO2016007235A1 (en) | 2014-07-11 | 2015-05-29 | Anti-pd-l1 antibodies and diagnostic uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021212093A Division JP2022061983A (ja) | 2014-07-11 | 2021-12-27 | 抗ｐｄ－ｌ１抗体及びその診断上の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017530691A JP2017530691A (ja) | 2017-10-19 |
| JP2017530691A5 true JP2017530691A5 (enExample) | 2018-07-12 |
| JP7032929B2 JP7032929B2 (ja) | 2022-03-09 |
Family
ID=53373660
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017501231A Active JP7032929B2 (ja) | 2014-07-11 | 2015-05-29 | 抗ｐｄ－ｌ１抗体及びその診断上の使用 |
| JP2021212093A Pending JP2022061983A (ja) | 2014-07-11 | 2021-12-27 | 抗ｐｄ－ｌ１抗体及びその診断上の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021212093A Pending JP2022061983A (ja) | 2014-07-11 | 2021-12-27 | 抗ｐｄ－ｌ１抗体及びその診断上の使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US20160009805A1 (enExample) |
| EP (2) | EP3309174B1 (enExample) |
| JP (2) | JP7032929B2 (enExample) |
| KR (1) | KR102360693B1 (enExample) |
| CN (1) | CN106604933B (enExample) |
| AU (1) | AU2015288232B2 (enExample) |
| BR (1) | BR112017000497B1 (enExample) |
| CA (1) | CA2954868C (enExample) |
| DK (1) | DK3309174T3 (enExample) |
| ES (1) | ES2916923T3 (enExample) |
| IL (1) | IL250032B (enExample) |
| MX (1) | MX384364B (enExample) |
| MY (1) | MY188940A (enExample) |
| RU (1) | RU2715038C2 (enExample) |
| SG (1) | SG11201700207WA (enExample) |
| WO (1) | WO2016007235A1 (enExample) |
| ZA (1) | ZA201700832B (enExample) |
Families Citing this family (148)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2625292B1 (en) | 2010-10-07 | 2018-12-05 | The General Hospital Corporation | Biomarkers of cancer |
| KR20220053691A (ko) | 2013-03-15 | 2022-04-29 | 제넨테크, 인크. | Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법 |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| US9909167B2 (en) | 2014-06-23 | 2018-03-06 | The Board Of Trustees Of The Leland Stanford Junior University | On-slide staining by primer extension |
| EP3760208B1 (en) | 2014-06-25 | 2024-05-29 | The General Hospital Corporation | Targeting human satellite ii (hsatii) |
| CA2954868C (en) | 2014-07-11 | 2023-08-29 | Genentech, Inc. | Anti-pd-l1 antibodies and diagnostic uses thereof |
| US10800846B2 (en) * | 2015-02-26 | 2020-10-13 | Merck Patent Gmbh | PD-1/PD-L1 inhibitors for the treatment of cancer |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| CN114533867A (zh) | 2015-03-27 | 2022-05-27 | 免疫生物公司 | 用于治疗癌症的被遗传修饰的nk-92细胞和单克隆抗体 |
| WO2016162368A1 (en) * | 2015-04-07 | 2016-10-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Non-invasive imaging of tumor pd-l1 expression |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| DK3291679T3 (da) | 2015-05-06 | 2022-01-17 | Snipr Tech Ltd | Ændring af mikrobielle populationer og modificering af mikrobiota |
| US10869924B2 (en) | 2015-06-16 | 2020-12-22 | Merck Patent Gmbh | PD-L1 antagonist combination treatments |
| CN107771076A (zh) | 2015-06-17 | 2018-03-06 | 豪夫迈·罗氏有限公司 | 使用pd‑1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法 |
| WO2016207646A1 (en) * | 2015-06-24 | 2016-12-29 | Immodulon Therapeutics Limited | A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy |
| RU2020124273A (ru) | 2015-08-11 | 2020-12-03 | Уси Байолоджикс (Кайман) Инк. | Новые анти-pd-1 антитела |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| KR20180069903A (ko) | 2015-11-02 | 2018-06-25 | 파이브 프라임 테라퓨틱스, 인크. | Cd80 세포외 도메인 폴리펩타이드 및 이들의 암 치료에서의 용도 |
| AU2016369623A1 (en) * | 2015-12-17 | 2018-06-28 | Novartis Ag | Combination of c-Met inhibitor with antibody molecule to PD-1 and uses thereof |
| BR112018067698A2 (pt) * | 2016-02-25 | 2019-01-08 | Cell Medica Switzerland Ag | células modificadas para imunoterapia |
| CN109476731A (zh) | 2016-02-29 | 2019-03-15 | 基础医药有限公司 | 治疗癌症的方法 |
| AU2017225854B2 (en) | 2016-02-29 | 2020-11-19 | Foundation Medicine, Inc. | Therapeutic and diagnostic methods for cancer |
| HK1247214B (zh) * | 2016-03-04 | 2019-07-19 | 四川科伦博泰生物医药股份有限公司 | 一种pdl-1抗体、其药物组合物及其用途 |
| MX2018010546A (es) | 2016-03-15 | 2019-02-20 | Chugai Pharmaceutical Co Ltd | Metodos de tratamiento de cancer que usan antagonistas de union al eje de muerte programada 1 (pd-1) y anticuerpos anti glipicano 3 (gpc3). |
| US10613092B2 (en) | 2016-04-01 | 2020-04-07 | Agilent Technologies, Inc. | Scoring methods for anti-PD therapy eligibility and compositions for performing same |
| ES2781474T3 (es) | 2016-04-07 | 2020-09-02 | Glaxosmithkline Ip Dev Ltd | Amidas heterocíclicas útiles como moduladores de proteínas |
| SG10201900628RA (en) | 2016-04-07 | 2019-02-27 | Glaxosmithkline Ip Dev Ltd | Heterocyclic amides useful as protein modulators |
| CA3016917A1 (en) | 2016-04-27 | 2017-11-02 | Immunomedics, Inc. | Efficacy of anti-trop-2-sn-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors |
| US12202856B2 (en) | 2016-05-19 | 2025-01-21 | The General Hospital Corporation | Tethered interleukin-2 to its receptor IL-2RBETA, a platform to enhance natural killer and regulatory T cell activity |
| WO2017201502A1 (en) * | 2016-05-20 | 2017-11-23 | Biohaven Pharmaceutical Holding Company Ltd. | Use of glutamate modulating agents with immunotherapies to treat cancer |
| GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
| WO2018029474A2 (en) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| CN109789228B (zh) * | 2016-07-27 | 2022-10-21 | 斯坦福大学托管董事会 | 高度复用荧光成像 |
| CN107686520B (zh) * | 2016-08-04 | 2023-01-03 | 信达生物制药(苏州)有限公司 | 抗pd-l1纳米抗体及其应用 |
| JP6925421B2 (ja) | 2016-08-05 | 2021-08-25 | ワイ−バイオロジクス・インコーポレイテッド | プログラム化された細胞死蛋白質リガンド−１（ｐｄ−ｌ１）に対する抗体及びその用途 |
| EP3497128A2 (en) | 2016-08-09 | 2019-06-19 | Kymab Limited | Anti-icos antibodies |
| AU2017329780B2 (en) | 2016-09-20 | 2024-11-14 | Merck Patent Gmbh | Diagnostic anti-PD-L1 antibody and use thereof |
| CN109863402A (zh) | 2016-09-27 | 2019-06-07 | 鼎航医药股份有限公司 | 基于β2-糖蛋白1水平的用巴维昔单抗治疗癌症的方法和其测定 |
| MX2019003934A (es) | 2016-10-06 | 2019-07-10 | Genentech Inc | Métodos terapéuticos y de diagnóstico para el cáncer. |
| IL265762B2 (en) | 2016-10-06 | 2024-04-01 | Merck Patent Gmbh | Dosing regimen of avelumab for the treatment of cancer |
| KR102687833B1 (ko) | 2016-11-02 | 2024-07-24 | 브리스톨-마이어스 스큅 컴퍼니 | 다발성 골수종 치료를 위한 bcma 및 cd3에 대응하는 이중 특이적 항체 및 면역학적 약물의 복합용도 |
| WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| WO2018089688A1 (en) | 2016-11-09 | 2018-05-17 | Jinjun Shi | Restoration of tumor suppression using mrna-based delivery system |
| WO2018156740A1 (en) | 2017-02-24 | 2018-08-30 | Macrogenics, Inc. | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof |
| WO2018154520A1 (en) | 2017-02-27 | 2018-08-30 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| MX2019010887A (es) | 2017-03-16 | 2019-10-15 | Alpine Immune Sciences Inc | Proteinas inmunomoduladoras de cb80 variante y usos de estas. |
| CN110914300A (zh) | 2017-04-03 | 2020-03-24 | 安康乐济股份有限公司 | 使用ps靶向抗体与免疫肿瘤学药剂治疗癌症的方法 |
| MX2019012295A (es) | 2017-04-14 | 2020-02-07 | Tollnine Inc | Polinucleotidos inmunomoduladores, conjugados de anticuerpos de los mismos y metodos para su uso. |
| JP7408396B2 (ja) | 2017-04-20 | 2024-01-05 | アーデーセー セラピューティクス ソシエテ アノニム | 併用療法 |
| AU2018253950A1 (en) | 2017-04-20 | 2019-09-19 | Adc Therapeutics Sa | Combination therapy with an anti-CD25 antibody-drug conjugate |
| AU2018258661A1 (en) | 2017-04-28 | 2019-10-17 | Five Prime Therapeutics, Inc. | Methods of treatment with CD80 extracellular domain polypeptides |
| EP3630838A1 (en) | 2017-06-01 | 2020-04-08 | CytomX Therapeutics, Inc. | Activatable anti-pdl1 antibodies, and methods of use thereof |
| BR112019026564A2 (pt) | 2017-06-14 | 2020-06-30 | Adc Therapeutics Sa | regimes de dosagem para a administração de um adc anti-cd19 |
| GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| CN107266572A (zh) * | 2017-07-13 | 2017-10-20 | 无锡傲锐东源生物科技有限公司 | 抗pd‑l1蛋白单克隆抗体及其用途 |
| MX2020000604A (es) * | 2017-07-21 | 2020-09-10 | Genentech Inc | Métodos terapéuticos y de diagnóstico para el cáncer. |
| US20210238172A1 (en) | 2017-10-05 | 2021-08-05 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators and methods of using the same |
| EP3692034A1 (en) | 2017-10-05 | 2020-08-12 | GlaxoSmithKline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (sting) |
| TW201938165A (zh) * | 2017-12-18 | 2019-10-01 | 美商輝瑞股份有限公司 | 治療癌症的方法及組合療法 |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| US11629189B2 (en) | 2017-12-19 | 2023-04-18 | Kymab Limited | Bispecific antibody for ICOS and PD-L1 |
| CN115925943A (zh) | 2017-12-27 | 2023-04-07 | 信达生物制药(苏州)有限公司 | 抗pd-l1抗体及其用途 |
| CN109970856B (zh) | 2017-12-27 | 2022-08-23 | 信达生物制药(苏州)有限公司 | 抗lag-3抗体及其用途 |
| WO2019129136A1 (zh) | 2017-12-27 | 2019-07-04 | 信达生物制药(苏州)有限公司 | 抗pd-l1抗体及其用途 |
| US20210213041A1 (en) | 2018-02-06 | 2021-07-15 | The General Hospital Corporation | Repeat rna as biomarkers of tumor immune response |
| MX2020008949A (es) | 2018-02-27 | 2021-01-08 | Incyte Corp | Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b. |
| US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
| CN108864284A (zh) * | 2018-04-02 | 2018-11-23 | 南京基诺米医疗科技有限公司 | 兔抗人pd-l1蛋白单克隆抗体制备及其免疫组化用途 |
| TWI878153B (zh) | 2018-04-09 | 2025-03-21 | 日商衛材R&D企管股份有限公司 | 特定普拉二烯內酯化合物及其使用方法 |
| AU2019252432B2 (en) | 2018-04-12 | 2023-04-13 | Eisai R&D Management Co., Ltd. | Pladienolide derivatives as spliceosome targeting agents for treating cancer |
| GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
| CA3100731A1 (en) | 2018-05-18 | 2019-11-21 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| CA3098103A1 (en) | 2018-05-23 | 2019-11-28 | Adc Therapeutics Sa | Molecular adjuvant |
| JOP20200268A1 (ar) | 2018-06-01 | 2020-10-26 | Eisai R&D Man Co Ltd | تضفير مترافقات عقار جسم مضاد معدل وطرق استخدامها |
| WO2019227490A1 (en) | 2018-06-01 | 2019-12-05 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Compositions and methods for imaging |
| CA3101205A1 (en) | 2018-06-01 | 2019-12-05 | Eisai R&D Management Co., Ltd. | Methods of using splicing modulators |
| CA3102398A1 (en) | 2018-06-03 | 2019-12-12 | Lamkap Bio Beta Ltd. | Bispecific antibodies against ceacam5 and cd47 |
| US12065476B2 (en) | 2018-06-15 | 2024-08-20 | Alpine Immune Sciences, Inc. | PD-1 variant immunomodulatory proteins and uses thereof |
| SG11202013216RA (en) | 2018-07-05 | 2021-01-28 | Incyte Corp | Fused pyrazine derivatives as a2a / a2b inhibitors |
| GB201811291D0 (en) | 2018-07-10 | 2018-08-29 | Univ Dublin City | A method of predicting response to treatment in cancer patients |
| CA3105381A1 (en) | 2018-07-11 | 2020-01-16 | The Brigham And Women's Hospital, Inc. | Methods and compositions for delivery of agents across the blood-brain barrier |
| EP3843849A1 (en) | 2018-08-27 | 2021-07-07 | Pieris Pharmaceuticals GmbH | Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereof |
| KR102084196B1 (ko) | 2018-08-29 | 2020-03-03 | 연세대학교 산학협력단 | 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트 |
| WO2020044206A1 (en) | 2018-08-29 | 2020-03-05 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors for use in the treatment cancer |
| CN108997500B (zh) * | 2018-09-12 | 2020-08-21 | 首都医科大学附属北京胸科医院 | 一种抗人pd-l1抗体及其应用 |
| AU2019342099A1 (en) * | 2018-09-19 | 2021-04-08 | Genentech, Inc. | Therapeutic and diagnostic methods for bladder cancer |
| KR20210089146A (ko) | 2018-09-19 | 2021-07-15 | 알파인 이뮨 사이언시즈, 인코포레이티드 | 변이체 cd80 단백질 및 관련 구축물의 방법 및 용도 |
| WO2020061349A1 (en) * | 2018-09-21 | 2020-03-26 | Genentech, Inc. | Diagnostic methods for triple-negative breast cancer |
| US11851663B2 (en) | 2018-10-14 | 2023-12-26 | Snipr Biome Aps | Single-vector type I vectors |
| CN113301899A (zh) | 2018-11-16 | 2021-08-24 | 艾科尔公司 | 用于治疗癌症的药物组合 |
| AU2019397062A1 (en) | 2018-12-13 | 2021-05-06 | Eisai R&D Management Co., Ltd. | Herboxidiene antibody-drug conjugates and methods of use |
| EP3914623A4 (en) * | 2019-01-23 | 2022-11-23 | Tayu Huaxia Biotech Medical Group Co., Ltd. | ANTI-PD-L1 DIABODIES AND THEIR USE |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| CN113396230A (zh) | 2019-02-08 | 2021-09-14 | 豪夫迈·罗氏有限公司 | 癌症的诊断和治疗方法 |
| TW202045544A (zh) * | 2019-02-22 | 2020-12-16 | 美商戊瑞治療有限公司 | 用於治療ＰＤ－Ｌ１陰性腫瘤之ＣＤ８０胞外結構域Ｆｃ融合蛋白 |
| CN110372793B (zh) * | 2019-03-21 | 2022-09-06 | 南京东极医药科技有限公司 | Pd-l1的纳米抗体及其临床应用 |
| EP3947640A4 (en) | 2019-04-02 | 2022-12-14 | The Brigham & Women's Hospital, Inc. | PROCEDURE FOR DETERMINING THE PROGRESSION OF PRIMARY MELANOMA |
| EP3969452A1 (en) | 2019-05-16 | 2022-03-23 | Stingthera, Inc. | Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use |
| CN114302875A (zh) | 2019-05-16 | 2022-04-08 | 斯汀塞拉股份有限公司 | 氧代吖啶基乙酸衍生物及使用方法 |
| GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| ES2975528T3 (es) | 2019-09-18 | 2024-07-08 | Lamkap Bio Alpha AG | Anticuerpos biespecíficos contra ceacam5 y cd3 |
| US11667709B2 (en) | 2019-09-24 | 2023-06-06 | Industrial Technology Research Institute | Anti-TIGIT antibodies and methods of use |
| MX2022004501A (es) | 2019-11-07 | 2022-05-06 | Oncxerna Therapeutics Inc | Clasificacion de microambientes tumorales. |
| GB201917254D0 (en) | 2019-11-27 | 2020-01-08 | Adc Therapeutics Sa | Combination therapy |
| EP3831849A1 (en) | 2019-12-02 | 2021-06-09 | LamKap Bio beta AG | Bispecific antibodies against ceacam5 and cd47 |
| WO2021119753A1 (en) | 2019-12-18 | 2021-06-24 | Ctxt Pty Limited | Compounds |
| WO2021138512A1 (en) * | 2020-01-03 | 2021-07-08 | Incyte Corporation | Combination therapy comprising a2a/a2b and pd-1/pd-l1 inhibitors |
| CA3167290A1 (en) | 2020-01-10 | 2021-07-15 | The Brigham And Women's Hospital, Inc. | Methods and compositions for delivery of immunotherapy agents across the blood-brain barrier to treat brain cancer |
| IL295759A (en) | 2020-02-28 | 2022-10-01 | Tallac Therapeutics Inc | Transglutaminase mediated coupling |
| WO2022008519A1 (en) | 2020-07-07 | 2022-01-13 | BioNTech SE | Therapeutic rna for hpv-positive cancer |
| WO2022036146A1 (en) | 2020-08-12 | 2022-02-17 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| ES2967381T3 (es) | 2020-12-18 | 2024-04-30 | Lamkap Bio Beta Ag | Anticuerpos biespecíficos contra CEACAM5 y CD47 |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| TW202304506A (zh) | 2021-03-25 | 2023-02-01 | 日商安斯泰來製藥公司 | 涉及抗claudin 18.2抗體的組合治療以治療癌症 |
| JP2024511166A (ja) | 2021-03-25 | 2024-03-12 | オンクセルナ セラピューティクス，インコーポレイテッド | 癌の標的療法 |
| WO2022243378A1 (en) | 2021-05-18 | 2022-11-24 | Kymab Limited | Uses of anti-icos antibodies |
| GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
| CN113444182B (zh) * | 2021-06-22 | 2022-07-19 | 四川大学华西医院 | 一种靶向递送IgG类抗体的融合蛋白载体及其用途 |
| JP2024525758A (ja) | 2021-07-13 | 2024-07-12 | ビオンテック・ソシエタス・エウロパエア | がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤 |
| WO2023051926A1 (en) | 2021-09-30 | 2023-04-06 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| WO2023079428A1 (en) | 2021-11-03 | 2023-05-11 | Pfizer Inc. | Combination therapies using tlr7/8 agonist |
| WO2023083439A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Tlr7 agonist and combinations for cancer treatment |
| EP4490173A1 (en) | 2022-03-07 | 2025-01-15 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses |
| CN114507286B (zh) * | 2022-04-18 | 2022-07-05 | 苏州百道医疗科技有限公司 | 一种抗pd-l1重组兔单克隆抗体及其应用 |
| US20250340641A1 (en) | 2022-05-18 | 2025-11-06 | Kymab Limited | Uses of anti-icos antibodies |
| CA3248576A1 (en) | 2022-06-16 | 2023-12-21 | Lamkap Bio Beta Ltd | POLYTHERAPY OF BISPECIFIC ANTIBODY AGAINST CEACAM5 AND CD47, AND BISPECIFIC ANTIBODY AGAINST CEACAM5 AND CD3 |
| GB202209518D0 (en) | 2022-06-29 | 2022-08-10 | Snipr Biome Aps | Treating & preventing E coli infections |
| CN120153254A (zh) | 2022-09-01 | 2025-06-13 | 基因泰克公司 | 膀胱癌的治疗和诊断方法 |
| JP2025541738A (ja) | 2022-12-01 | 2025-12-23 | ビオンテック・ソシエタス・エウロパエア | 抗ｐｄ１ａｂと化学療法での併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性抗体 |
| EP4634224A1 (en) | 2022-12-14 | 2025-10-22 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
| WO2024160721A1 (en) | 2023-01-30 | 2024-08-08 | Kymab Limited | Antibodies |
| WO2024228167A1 (en) | 2023-05-03 | 2024-11-07 | Iox Therapeutics Inc. | Inkt cell modulator liposomal compositions and methods of use |
| WO2025042742A1 (en) | 2023-08-18 | 2025-02-27 | Bristol-Myers Squibb Company | Compositions comprising antibodies that bind bcma and cd3 and methods of treatment |
| WO2025056180A1 (en) | 2023-09-15 | 2025-03-20 | BioNTech SE | Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists |
| WO2025085404A1 (en) | 2023-10-16 | 2025-04-24 | Genentech, Inc. | Diagnostic and therapeutic methods for treating lung cancer |
| WO2025121445A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2025174933A1 (en) | 2024-02-14 | 2025-08-21 | Genentech, Inc. | Methods for treatment of pancreatic cancer with anti-pd-l1 ab, anti-tigit ab, gemcitabine and nab-placlitaxel |
| CN120405153B (zh) * | 2025-07-04 | 2025-11-21 | 军科正源（北京）药物研究有限责任公司 | 双抗药物的中和抗体的检测方法 |
Family Cites Families (140)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| WO1993016185A2 (en) | 1992-02-06 | 1993-08-19 | Creative Biomolecules, Inc. | Biosynthetic binding protein for cancer marker |
| MD1367C2 (ro) | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
| US5922855A (en) | 1993-12-17 | 1999-07-13 | Oregon Health Sciences University | Mammalian DNA mismatch repair genes MLH1 and PMS1 |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| ES2244066T3 (es) | 1997-06-24 | 2005-12-01 | Genentech, Inc. | Procedimiento y composiciones de glicoproteinas galactosiladas. |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| ATE350472T1 (de) | 1997-10-21 | 2007-01-15 | Univ Glasgow | Jmy, mit-aktivator für p300/cbp, dafür kodierendenucleinsäure und deren verwendungen |
| DE69840412D1 (de) | 1997-10-31 | 2009-02-12 | Genentech Inc | Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen |
| ES2375931T3 (es) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | Humanización de anticuerpo murino. |
| AU3369999A (en) | 1998-04-02 | 1999-10-25 | Genentech Inc. | Antibody variants and fragments thereof |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| NZ539776A (en) | 1999-01-15 | 2006-12-22 | Genentech Inc | Polypeptide variants with altered effector function |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| BR0013542A (pt) | 1999-08-23 | 2002-05-14 | Dana Farber Cancer Inst Inc | Moléculas b7-4 e usos para as mesmas |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| PT1222292E (pt) | 1999-10-04 | 2005-11-30 | Medicago Inc | Metodo para regulacao da transcricao de genes exogenos na presenca de azoto |
| AU7950400A (en) | 1999-10-19 | 2001-04-30 | Kyowa Hakko Kogyo Co. Ltd. | Process for producing polypeptide |
| EP3225632B1 (en) | 1999-11-30 | 2020-05-06 | Mayo Foundation for Medical Education and Research | Antibodies binding to b7-h1, a novel immunoregulatory molecule |
| US6803192B1 (en) | 1999-11-30 | 2004-10-12 | Mayo Foundation For Medical Education And Research | B7-H1, a novel immunoregulatory molecule |
| JP2003531588A (ja) | 2000-04-11 | 2003-10-28 | ジェネンテック・インコーポレーテッド | 多価抗体とその用途 |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| CA2424602C (en) | 2000-10-06 | 2012-09-18 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-producing cell |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| EP2180044A1 (en) | 2001-08-03 | 2010-04-28 | GlycArt Biotechnology AG | Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity |
| MXPA04003798A (es) | 2001-10-25 | 2004-07-30 | Genentech Inc | Composiciones de glicoproteina. |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
| AU2003236019A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism |
| PL373256A1 (en) | 2002-04-09 | 2005-08-22 | Kyowa Hakko Kogyo Co, Ltd. | Cells with modified genome |
| JPWO2003085118A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物の製造方法 |
| AU2003236017B2 (en) | 2002-04-09 | 2009-03-26 | Kyowa Kirin Co., Ltd. | Drug containing antibody composition |
| JPWO2003085119A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物のＦｃγ受容体ＩＩＩａに対する結合活性を高める方法 |
| ATE261126T1 (de) | 2002-08-01 | 2004-03-15 | Mtm Lab Ag | Verfahren für lösung-basierte diagnose |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| TWI335821B (en) | 2002-12-16 | 2011-01-11 | Genentech Inc | Immunoglobulin variants and uses thereof |
| JPWO2005035586A1 (ja) | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | 融合蛋白質組成物 |
| EP1705251A4 (en) | 2003-10-09 | 2009-10-28 | Kyowa Hakko Kirin Co Ltd | PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY RNA INHIBITION OF FUNCTION OF $ G (A) 1,6-FUCOSYLTRANSFERASE |
| NO347530B1 (no) | 2003-11-05 | 2023-12-11 | Roche Glycart Ag | Et humanisert type II anti-CD20 antistoff og vertscelle som produserer et humanisert type II anti-CD20 antistoff samt en fremgangsmåte for fremstilling og en farmasøytisk sammensetning. |
| WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
| RU2386638C2 (ru) | 2004-03-31 | 2010-04-20 | Дженентек, Инк. | Гуманизированные анти-тфр-бета-антитела |
| CN1942483B (zh) | 2004-04-13 | 2012-09-26 | 弗·哈夫曼-拉罗切有限公司 | 抗p型选凝素抗体 |
| AU2012211347B9 (en) | 2004-07-20 | 2015-06-18 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| BRPI0516284A (pt) | 2004-09-23 | 2008-09-02 | Genentech Inc | anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto |
| ZA200703482B (en) | 2004-10-06 | 2008-09-25 | Mayo Foundation | B7-H1 and methods of diagnosis, prognosis, and treatment of cancer |
| SI3428191T1 (sl) | 2004-10-06 | 2025-03-31 | Mayo Foundation For Medical Education And Research | B7-H1 in PD-1 v zdravljenju karcinoma ledvičnih celic |
| CA2970873C (en) | 2005-05-09 | 2022-05-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| MX351401B (es) | 2005-06-08 | 2017-10-13 | Dana Farber Cancer Inst Inc | Metodos y composiciones para el tratamiento de infecciones persistentes y cancer por inhibicion de la ruta de muerte celular programada (pd-1). |
| EA019344B1 (ru) * | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
| EP1777523A1 (en) | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
| KR20080073711A (ko) | 2005-10-21 | 2008-08-11 | 바이엘 헬스케어 엘엘씨 | 암의 예측 및 예후 방법, 및 암 치료 모니터링 방법 |
| US20100015642A1 (en) | 2006-01-05 | 2010-01-21 | Kwon Eugene D | B7-h1 and survivin in cancer |
| US20090215084A1 (en) | 2006-01-05 | 2009-08-27 | Mayo Foundation For Medical Education And Research | B7-h1 and b7-h4 in cancer |
| CN101104640A (zh) | 2006-07-10 | 2008-01-16 | 苏州大学 | 抗人pd-l1单克隆抗体制备及应用 |
| US7895540B2 (en) | 2006-08-02 | 2011-02-22 | Georgia Tech Research Corporation | Multilayer finite difference methods for electrical modeling of packages and printed circuit boards |
| EP2059533B1 (en) | 2006-08-30 | 2012-11-14 | Genentech, Inc. | Multispecific antibodies |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| AU2008220419A1 (en) | 2007-02-28 | 2008-09-04 | The Procter & Gamble Company | Methods and targets for identifying compounds for regulating rhinovirus infection |
| US20080299555A1 (en) | 2007-05-30 | 2008-12-04 | Hiroaki Nitta | Multicolor chromogenic detection of biomarkers |
| PL2235064T3 (pl) | 2008-01-07 | 2016-06-30 | Amgen Inc | Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych |
| BRPI0907718A2 (pt) | 2008-02-11 | 2017-06-13 | Curetech Ltd | método para tratar um tumor, método para melhorar a tolerabilidade a pelo menos um agente quimiterápico, método para aumentar a sobrevida de um indivíduo que tem um tumor, método para reduzir ou prevenir recidiva tumoral, uso de um anticorpo monoclonal humanizado ou seu fragmento e anticorpo monoclonal humanizado ou seu fragmento |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| EA201170375A1 (ru) | 2008-08-25 | 2012-03-30 | Эмплиммьюн, Инк. | Антагонисты pd-1 и способы их применения |
| BRPI0919377A2 (pt) | 2008-09-26 | 2016-09-27 | Dana Farber Cancer Inst Inc | anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento |
| FI4209510T3 (fi) | 2008-12-09 | 2024-03-22 | Hoffmann La Roche | Anti-PD-L1-vasta-aineita ja niiden käyttö T-solutoiminnan tehostamiseksi |
| ES2629337T3 (es) | 2009-02-09 | 2017-08-08 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos |
| WO2010101249A1 (ja) | 2009-03-06 | 2010-09-10 | 国立大学法人三重大学 | Ｔ細胞の機能増強方法 |
| US8709417B2 (en) | 2009-09-30 | 2014-04-29 | Memorial Sloan-Kettering Cancer Center | Combination immunotherapy for the treatment of cancer |
| JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害 |
| LT3279215T (lt) | 2009-11-24 | 2020-04-10 | Medimmune Limited | Tiksliniai surišantys agentai prieš b7-h1 |
| EP2588443A2 (en) | 2010-07-02 | 2013-05-08 | Ventana Medical Systems, Inc. | Hapten conjugates for target detection |
| MY166040A (en) | 2010-09-15 | 2018-05-21 | Almac Diagnostics Ltd | Molecular diagnostic test for cancer |
| RS57324B1 (sr) | 2011-04-20 | 2018-08-31 | Medimmune Llc | Antitela i drugi molekuli koji vezuju b7-h1 i pd-1 |
| WO2012154983A2 (en) | 2011-05-10 | 2012-11-15 | Biocare Medical, Llc | Systems and methods for anti-pax8 antibodies |
| CN102250911A (zh) | 2011-05-31 | 2011-11-23 | 苏州大学 | 一种可溶性b7-h1定量检测试剂盒 |
| TW202114735A (zh) | 2011-08-01 | 2021-04-16 | 美商建南德克公司 | 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法 |
| EP3763741A1 (en) | 2011-11-28 | 2021-01-13 | Merck Patent GmbH | Anti-pd-l1 antibodies and uses thereof |
| EP2823066A4 (en) | 2012-03-06 | 2015-11-11 | Advanced Cell Diagnostics Inc | CHROMOGENIC DUPLEX ASSAY FOR THE IN-SITU DETECTION OF NUCLEIC ACIDS |
| EP2831587B1 (en) | 2012-03-27 | 2018-05-16 | Ventana Medical Systems, Inc. | Signaling conjugates and methods of use |
| WO2013172926A1 (en) | 2012-05-14 | 2013-11-21 | Yale University | Immune biomarkers and assays predictive of clinical response to immunotherapy for cancer |
| KR102418979B1 (ko) | 2012-05-15 | 2022-07-11 | 브리스톨-마이어스 스큅 컴퍼니 | Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법 |
| WO2013173233A1 (en) * | 2012-05-17 | 2013-11-21 | Baker Hughes Incorporated | Dendritic surfactants and extended surfactants for drilling fluid formulations |
| US9845356B2 (en) | 2012-08-03 | 2017-12-19 | Dana-Farber Cancer Institute, Inc. | Single agent anti-PD-L1 and PD-L2 dual binding antibodies and methods of use |
| EP3446709A1 (en) | 2012-08-07 | 2019-02-27 | F. Hoffmann-La Roche AG | Combination therapy for the treatment of glioblastoma |
| BR112015012644A2 (pt) | 2012-11-30 | 2017-12-19 | Hoffmann La Roche | método para determinar a necessidade de um paciente com câncer, método de tratamento do câncer, composição farmacêutica, uso de um ácido nucleico ou anticorpo e kit; |
| WO2014100220A2 (en) | 2012-12-18 | 2014-06-26 | Biocare Medical, Llc | Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer |
| AR093984A1 (es) * | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| ES2720483T3 (es) | 2013-02-28 | 2019-07-22 | Biocare Medical Llc | Sistemas y procedimientos de anticuerpos anti p40 |
| WO2014165082A2 (en) * | 2013-03-13 | 2014-10-09 | Medimmune, Llc | Antibodies and methods of detection |
| US20150071910A1 (en) | 2013-03-15 | 2015-03-12 | Genentech, Inc. | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
| KR20220053691A (ko) | 2013-03-15 | 2022-04-29 | 제넨테크, 인크. | Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법 |
| EP2978863B1 (en) | 2013-03-28 | 2021-03-10 | Advanced Cell Diagnostics, Inc. | Differentiation between transient and persistent high risk hpv infection by in situ hybridization |
| US20160084839A1 (en) | 2013-04-02 | 2016-03-24 | Marisa Dolled-Filhart | Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue |
| WO2014194293A1 (en) | 2013-05-30 | 2014-12-04 | Amplimmune, Inc. | Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof |
| EP3024850A4 (en) | 2013-07-24 | 2017-05-03 | Dana-Farber Cancer Institute, Inc. | Anti-galectin-1 monoclonal antibodies and fragments thereof |
| GB201316027D0 (en) | 2013-09-09 | 2013-10-23 | Almac Diagnostics Ltd | Molecular diagnostic test for oesophageal cancer |
| GB201316024D0 (en) | 2013-09-09 | 2013-10-23 | Almac Diagnostics Ltd | Molecular diagnostic test for lung cancer |
| WO2015038538A1 (en) | 2013-09-10 | 2015-03-19 | Medimmune, Llc | Compositions and methods for treating sepsis |
| MX370818B (es) | 2013-09-11 | 2020-01-08 | Medimmune Ltd | Anticuerpos anti-b7-h1 para tratar tumores. |
| CA2942081C (en) | 2013-10-11 | 2021-09-07 | Ventana Medical Systems, Inc. | Multiplex her2 and estrogen receptor co-staining assays for detecting tumor heterogeneity |
| EP3060581A4 (en) * | 2013-10-25 | 2017-06-07 | Dana-Farber Cancer Institute, Inc. | Anti-pd-l1 monoclonal antibodies and fragments thereof |
| US10241115B2 (en) | 2013-12-10 | 2019-03-26 | Merck Sharp & Dohme Corp. | Immunohistochemical proximity assay for PD-1 positive cells and PD-ligand positive cells in tumor tissue |
| JP6644713B2 (ja) | 2014-02-24 | 2020-02-12 | ヴェンタナ メディカル システムズ， インク． | キノンメチドアナログシグナル増幅 |
| US20150322184A1 (en) | 2014-05-07 | 2015-11-12 | Chevron Phillips Chemical Company Lp | High Performance Moisture Barrier Films at Lower Densities |
| EP3194554A4 (en) | 2014-05-12 | 2018-04-25 | The Procter and Gamble Company | Anti-microbial cleaning composition |
| WO2015181342A1 (en) | 2014-05-29 | 2015-12-03 | Spring Bioscience Corporation | Pd-l1 antibodies and uses thereof |
| CA2947687C (en) * | 2014-05-30 | 2021-07-06 | Ventana Medical Systems, Inc. | Multiplex assay for improved scoring of tumor tissues stained for pd-l1 |
| DK3152577T3 (en) | 2014-06-06 | 2018-10-01 | Ventana Med Syst Inc | SIGNIFICANCE OF INTRATUMORAL HER2 HETEROGENITY IN BREAST CANCER AND APPLICATIONS HEFAR |
| CA2954868C (en) * | 2014-07-11 | 2023-08-29 | Genentech, Inc. | Anti-pd-l1 antibodies and diagnostic uses thereof |
| ES2707970T3 (es) | 2014-09-29 | 2019-04-08 | Ventana Med Syst Inc | Ensayo múltiple de detección simultánea de gen-proteína de TP53/CEN17/linfocito B y sondas excepcionalmente específicas para 19q12, INSR, ATM, DLEU2, TP53 y 13q12 |
| ES2893100T3 (es) | 2015-10-12 | 2022-02-08 | Advanced Cell Diagnostics Inc | Detección in situ de variantes de nucleótidos en muestras con un elevado nivel de ruido, y composiciones y métodos relacionados con ésta |
| EP3377530B1 (en) * | 2015-11-22 | 2021-06-30 | Ventana Medical Systems, Inc. | Methods of identifying immune cells in pd-l1 positive tumor tissue |
-
2015
- 2015-05-29 CA CA2954868A patent/CA2954868C/en active Active
- 2015-05-29 ES ES17188907T patent/ES2916923T3/es active Active
- 2015-05-29 KR KR1020177003488A patent/KR102360693B1/ko active Active
- 2015-05-29 RU RU2017103495A patent/RU2715038C2/ru active
- 2015-05-29 MX MX2017000419A patent/MX384364B/es unknown
- 2015-05-29 DK DK17188907.4T patent/DK3309174T3/da active
- 2015-05-29 CN CN201580047724.4A patent/CN106604933B/zh active Active
- 2015-05-29 EP EP17188907.4A patent/EP3309174B1/en active Active
- 2015-05-29 AU AU2015288232A patent/AU2015288232B2/en active Active
- 2015-05-29 US US14/726,329 patent/US20160009805A1/en not_active Abandoned
- 2015-05-29 BR BR112017000497-6A patent/BR112017000497B1/pt active IP Right Grant
- 2015-05-29 MY MYPI2017000043A patent/MY188940A/en unknown
- 2015-05-29 SG SG11201700207WA patent/SG11201700207WA/en unknown
- 2015-05-29 WO PCT/US2015/033395 patent/WO2016007235A1/en not_active Ceased
- 2015-05-29 JP JP2017501231A patent/JP7032929B2/ja active Active
- 2015-05-29 EP EP15728355.7A patent/EP3166974A1/en not_active Withdrawn
-
2017
- 2017-01-10 IL IL250032A patent/IL250032B/en active IP Right Grant
- 2017-02-02 ZA ZA2017/00832A patent/ZA201700832B/en unknown
- 2017-10-06 US US15/727,388 patent/US10689445B2/en active Active
-
2020
- 2020-05-11 US US16/872,158 patent/US11530269B2/en active Active
-
2021
- 2021-12-27 JP JP2021212093A patent/JP2022061983A/ja active Pending
-
2022
- 2022-11-21 US US18/057,465 patent/US20230159641A1/en active Pending